Fidelis Capital Partners LLC Has $510,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fidelis Capital Partners LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 918 shares of the company’s stock after buying an additional 347 shares during the period. Fidelis Capital Partners LLC’s holdings in IDEXX Laboratories were worth $510,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of IDEXX Laboratories during the third quarter worth approximately $25,000. Valley National Advisers Inc. raised its stake in shares of IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after buying an additional 22 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd bought a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $28,000. Finally, Covestor Ltd raised its stake in shares of IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after buying an additional 28 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $2.30 during mid-day trading on Friday, reaching $475.49. 92,792 shares of the company were exchanged, compared to its average volume of 422,732. The company’s 50-day simple moving average is $539.94 and its 200-day simple moving average is $508.49. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $39.49 billion, a P/E ratio of 47.45, a P/E/G ratio of 3.68 and a beta of 1.26. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.05 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Insider Activity

In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on IDXX. Barclays upped their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a report on Tuesday, January 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $591.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.